Considering the increased risk of thyroid neoplasms in POT1 germline mutation carriers, Wilson et al. [107] recommend these patients be subjected to thyroid US follow-up every one to two years in addition to regular six-month dermatological checks and age-appropriate tumor screening. Here, POT1 is linked to neoplasm.